BioCentury
ARTICLE | Clinical News

RP128: The joint venture between Allelix Biopharmaceuticals (TSE:AXB) and Nordion International began a Phase I trial in normal volunteers to assess safety and

October 23, 1995 7:00 AM UTC

Resolution Pharmaceuticals Inc., Toronto Product: RP128, peptide-based radiopharmaceutical Indication: Imaging inflammation Status: The joint venture between Allelix Biopharmaceuticals (TSE:AXB) and N...